NASDAQ:ADAP Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $1.10 +0.01 (+0.92%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.06▼$1.1250-Day Range$1.09▼$1.8752-Week Range$1.01▼$2.65Volume562,736 shsAverage Volume1.02 million shsMarket Capitalization$170.13 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Adaptimmune Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside456.4% Upside$6.12 Price TargetShort InterestBearish1.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 5 Articles This WeekInsider TradingSelling Shares$113,002 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.63) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector590th out of 1,005 stocksBiological Products, Except Diagnostic Industry104th out of 168 stocks 3.4 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.12, Adaptimmune Therapeutics has a forecasted upside of 456.4% from its current price of $1.10.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.98% of the float of Adaptimmune Therapeutics has been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently increased by 1.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAP. Previous Next 3.1 News and Social Media Coverage News SentimentAdaptimmune Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search Interest34 people have searched for ADAP on MarketBeat in the last 30 days. This is an increase of 3,300% compared to the previous 30 days.MarketBeat Follows11 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $113,002.00 in company stock.Percentage Held by Insiders17.37% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($0.63) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adaptimmune Therapeutics (NASDAQ:ADAP) StockAdaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.Read More Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at Bryan, Garnier & CoMarch 24, 2023 | marketwatch.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of TCR2 Therapeutics Inc. (TCRR)March 26, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 16, 2023 | americanbankingnews.comAdaptimmune Therapeutics (NASDAQ:ADAP) Receives New Coverage from Analysts at StockNews.comMarch 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Foghorn Therapeutics (FHTX) and Rain Therapeutics (RAIN)March 8, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) ForecastsMarch 8, 2023 | finance.yahoo.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call TranscriptMarch 6, 2023 | marketwatch.comTCR Therapeutics Shares Rise, Adaptimmune ADS's Slide on Tie-UpMarch 26, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 6, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: CTI BioPharma (CTIC), Adaptimmune Therapeutics (ADAP)March 6, 2023 | bizjournals.comAdaptimmune to acquire Boston-area cell therapy company TCR² TherapeuticsMarch 6, 2023 | finance.yahoo.comAdaptimmune Agrees To Merge With Another Cell Therapy Focused CompanyMarch 6, 2023 | marketwatch.comAdaptimmune to Buy TCR Therapeutics in $103M Stock Swap >ADAP TRCCMarch 6, 2023 | msn.comAdaptimmune Craters after Acquiring TCR² TherapeuticsMarch 6, 2023 | finance.yahoo.comAdaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business UpdateMarch 6, 2023 | marketwatch.comNeuroblastoma Treatment Industry (Views and Position) 2023-2028March 3, 2023 | msn.comAdaptimmune Therapeutics's Earnings OutlookFebruary 28, 2023 | marketwatch.comTCR-Based Antibody Market 2023: Growth by 2029 Top Players with OpportunitiesFebruary 26, 2023 | benzinga.comAdaptimmune Therapeutics Stock (NASDAQ:ADAP), Quotes and News SummaryFebruary 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Infinity Pharma (INFI) and Leap Therapeutics (LPTX)February 23, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Biora Therapeutics (BIOR), IN8bio (INAB)February 22, 2023 | finance.yahoo.comAdaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023February 16, 2023 | finance.yahoo.comAdaptimmune Announces Changes to Board of DirectorsJanuary 18, 2023 | marketwatch.comAn Overview of Neuroblastoma Treatment Market, Major Participants, and Prospects by 2028January 9, 2023 | finance.yahoo.comPublication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial SarcomaJanuary 8, 2023 | finance.yahoo.comEven after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five yearsJanuary 6, 2023 | benzinga.comPneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of DirectorsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Company Calendar Last Earnings11/04/2021Today3/25/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees494Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.12 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+513.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,460,000.00 Net Margins-609.46% Pretax Margin-600.26% Return on Equity-132.29% Return on Assets-45.05% Debt Debt-to-Equity RatioN/A Current Ratio3.96 Quick Ratio3.96 Sales & Book Value Annual Sales$27.15 million Price / Sales6.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book2.20Miscellaneous Outstanding Shares154,660,000Free Float127,796,000Market Cap$170.13 million OptionableOptionable Beta2.22 Key ExecutivesAdrian RawcliffeChief Executive Officer & DirectorWilliam C. BertrandChief Operating OfficerGavin WoodChief Financial OfficerJoanna BrewerChief Scientific OfficerElliot NorryChief Medical OfficerKey CompetitorsTenaya TherapeuticsNASDAQ:TNYASorrento TherapeuticsNASDAQ:SRNEC4 TherapeuticsNASDAQ:CCCCAcumen PharmaceuticalsNASDAQ:ABOSFusion PharmaceuticalsNASDAQ:FUSNView All CompetitorsInsiders & InstitutionsMorgan StanleyBought 22,082 shares on 2/15/2023Ownership: 1.398%Endurant Capital Management LPSold 55,281 shares on 2/15/2023Ownership: 1.058%Millennium Management LLCBought 153,255 shares on 2/15/2023Ownership: 0.101%Lazard Asset Management LLCBought 98,590 shares on 2/15/2023Ownership: 0.060%Virtu Financial LLCSold 10,400 shares on 2/15/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions ADAP Stock - Frequently Asked Questions Should I buy or sell Adaptimmune Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAP shares. View ADAP analyst ratings or view top-rated stocks. What is Adaptimmune Therapeutics' stock price forecast for 2023? 5 Wall Street analysts have issued twelve-month price targets for Adaptimmune Therapeutics' shares. Their ADAP share price forecasts range from $3.00 to $10.00. On average, they predict the company's share price to reach $6.12 in the next year. This suggests a possible upside of 456.4% from the stock's current price. View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts. How have ADAP shares performed in 2023? Adaptimmune Therapeutics' stock was trading at $1.46 on January 1st, 2023. Since then, ADAP stock has decreased by 24.7% and is now trading at $1.10. View the best growth stocks for 2023 here. When is Adaptimmune Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our ADAP earnings forecast. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biotechnology company earned $1.20 million during the quarter, compared to analyst estimates of $1.20 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 132.29% and a negative net margin of 609.46%. During the same quarter in the prior year, the firm posted ($0.23) EPS. What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO? 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG). When did Adaptimmune Therapeutics IPO? (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. What is Adaptimmune Therapeutics' stock symbol? Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP." Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.10%), Bank of America Corp DE (2.89%), Morgan Stanley (1.40%), Endurant Capital Management LP (1.06%), Key Client Fiduciary Advisors LLC (0.18%) and Millennium Management LLC (0.10%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, William C Bertrand Jr and William C Bertrand, Jr. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adaptimmune Therapeutics' stock price today? One share of ADAP stock can currently be purchased for approximately $1.10. How much money does Adaptimmune Therapeutics make? Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $170.13 million and generates $27.15 million in revenue each year. The biotechnology company earns $-165,460,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. How many employees does Adaptimmune Therapeutics have? The company employs 494 workers across the globe. How can I contact Adaptimmune Therapeutics? Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001. This page (NASDAQ:ADAP) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.